ArticleScientific reports2024
Temporal trends of thyroid cancer in China and globally from 1990 to 2021: an analysis of the global burden of Disease Study 2021.
Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed.
- Signaling pathways and targeted therapy in high‑risk refractory thyroid cancer: From bench to bedside (Review).International journal of oncology · 2026Review
- Clinical and pathological profile with prognostic insights in 9504 thyroid cancer cases: a single-center study (2008-2023).Journal of the Endocrine Society · 2026Article
- Association Between Post-Traumatic Growth and Stigma Among Post-Thyroidectomy Patients: An Explanatory Sequential Mixed-Methods Study.Psychiatry investigation · 2026Article
- Early Birds and Thyroid Cancer: Unveiling the Link Between Morningness and Thyroid Cancer Risk Through Mendelian Randomization.Brain and behavior · 2026Article
- Retinal and Optic-Disc Changes Associated With ¹³¹I Therapy in Papillary Thyroid Carcinoma and Their Determinants.Investigative ophthalmology & visual science · 2026Article
- RET Signaling Pathway in Human Cancer: Oncogenic Mechanisms, Selective Inhibitors, and Emerging Resistance Strategies.International journal of molecular sciences · 2026Review
- Transforming thyroid disease education: AI and virtual technologies in residency training.Frontiers in endocrinology · 2026Review
- Trends in the Disease Burden of Migraine Among Women of Reproductive Age (15-49 Years) in Low- and Middle-Income Countries, 1990-2023.International journal of women's health · 2026Article
- The Heterogeneous Global Burden of Hemoglobinopathies Among Women of Childbearing Age, 1990-2021, with Projection to 2030.International journal of women's health · 2026Article
- Cytological Classification Diagnosis for Thyroid Nodules via Multimodal Model Deep Learning.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Article
- Comparative trends in pancreatic cancer burden and risk factors in the USA and China (1990-2021): insights from GBD analysis.BMC gastroenterology · 2025Article
- Tangeretin induces apoptosis and cell cycle arrest in thyroid cancer cells.Toxicological research · 2025Article
- Lomibuvir sensitizes radioiodine-resistant thyroid cancer cell lines to radioiodine treatment by targeting hTERT RNA-dependent polymerase activity.Journal of endocrinological investigation · 2025Article
- FTOZhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2025Article
- A Scoping Review on the Prevalence of Hashimoto's Thyroiditis and the Possible Associated Factors.Medical sciences (Basel, Switzerland) · 2025Article
- Retinal Structure and Microcirculation Alterations in Patients With Papillary Thyroid Carcinoma: An Optical Coherence Tomography and Angiography Study.Investigative ophthalmology & visual science · 2025Article
- Global trend and disparity in the burden of thyroid cancer attributable to high body-mass index from 1990 to 2021 and projection to 2049: a systematic analysis based on the Global Burden of Disease Study 2021.BMC public health · 2025Article
- Association between triglyceride-glucose index and papillary thyroid carcinoma among Chinese adults with thyroid nodules.Frontiers in endocrinology · 2025Article
- Epidemiological study of thyroid cancer at global, regional, and national levels from 1990 to 2021: an analysis derived from the Global Burden of Disease Study 2021.Frontiers in endocrinology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
The incidence of thyroid cancer (TC) is increasing annually worldwide, with a growing burden. This study aims to analyze temporal trends in the burden of TC by age and sex in China and globally from 1990 to 2021, including incidence, prevalence, mortality, and disability-adjusted life years (DALYs) rates, and to predict future trends. We obtained data on TC in China and globally from 1990 to 2021 from the Global Burden of Disease (GBD) database. Using the Joinpoint regression model, we calculated and analyzed the trends in age-standardized incidence rate (ASIR), age-standardized prevalence rate (ASPR), age-standardized mortality rate (ASMR), and age-standardized DALYs rate (ASDR). Specifically, we estimated the annual percent change (APC), the average annual percent change (AAPC), and the corresponding 95% confidence intervals (95% CI) for each metric. Additionally, we conducted a decomposition analysis to investigate the impact of aging, population growth, and epidemiological factors on the incidence and mortality rates of TC. Furthermore, the autoregressive integrated moving average (ARIMA) model was employed to predict the burden of TC from 2022 to 2036. From 1990 to 2021, the ASIR for TC in China increased from 1.249 (95% uncertainty interval [UI]: 1.009-1.473) per 100,000 to 2.473 (95% UI: 1.993-3.088) per 100,000. Conversely, the ASMR decreased from 0.473 (95% UI: 0.403-0.550) per 100,000 to 0.387 (95% UI: 0.307-0.472) per 100,000. Both males and females demonstrated an upward trajectory in ASIR. However, while the ASMR for females decreased, that for males showed an overall increase despite a decline in the last decade. The age of peak onset for TC ranged from 30 to 79 years, whereas the age of peak mortality was between 50 and 89 years. The analysis using the AAPC indicates that the growth in the ASIR (AAPC = 2.242, 95% CI: 2.112-2.371) and ASPR (AAPC = 2.975, 95% CI: 2.833-3.117) in China exceeds the global rate. Furthermore, the reduction in ASMR (AAPC = -0.651, 95% CI: -0.824 - -0.479) and ASDR (AAPC = -0.590, 95% CI: -0.787 - -0.392) in China is also more pronounced than globally. Decomposition analysis indicates that the increasing TC burden in China is primarily driven by population aging, whereas globally, population growth plays a more significant role. Projections based on predictive models suggest that from 2021 to 2036, the ASIR for both China and the global population is expected to continue rising, while the ASMR is anticipated to decline further. The incidence rates of TC in China and globally have shown a continuous upward trend, which is expected to persist over the next 15 years. Additionally, although the number of male TC cases is relatively lower compared to females, the overall ASMR and ASDR for males have shown an upward trend, despite a slight decline in recent years. This highlights the need to enhance prevention, diagnosis, and treatment measures, and to develop differentiated screening and treatment strategies based on age and sex.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.